NCT05548296Phase 2Recruiting

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

Study sponsor: Acrivon Therapeutics

Primary completion is the date data collection ends for the main study measures, not when results are published.

Primary completion2027-05-30Estimated
Enrollment · participants350Estimated
Source updated2026-08-21Last update listed in the registry record

Changes to this trial

Last 12 months
Filters
Clear filters

· 1 field changed

Planned enrollment decreased by 51 participants

Before: 401 participants (planned). After: 350 participants (planned).

Check registry source

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Before: Measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive. Measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative. Measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (All-Comers).. After: Measure: Arm 1: Anti-tumor activity of ACR-368 in Endometrial cancer subjects that are OncoSignature Positive. Measure: Arm 2: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects that are OncoSignature Negative. Measure: Arm 3: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers). Measure: Arm 4: Anti-tumor activity of ACR-368 with ULDG sensitization in Endometrial cancer subjects (Serous All-Comers)..

Planned enrollment increased by 48 participants

Before: 353 participants (planned). After: 401 participants (planned).

Primary completion date changed

Before: 31 Oct 2026. After: 30 May 2027.

Check registry source

Explore older trial changes

Upgrade to Pro to see the full available history for this trial.

Upgrade to Pro Illustrative preview